SBIR/STTR Research Award

Stream Dx: Point of Care Cellular Enabled IoT Communication Hub for Improved Diagnosis, Monitoring, and Post-Treatment Evaluation of LUTS

Award identifier 609d9f4679156b2b57171ffabb76e7bd50b845174b871164ef5c6d1e70f8b5acAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$2,971,064

Program and phase

SBIR · Phase II

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
STREAM DX, INC
Proposal award date
2019-09-05
Contract end date
2022-08-31
UEI
HVDUCDJQ2V95
Solicitation number
PA18-574
Topic code
400

Research abstract

PROJECT SUMMARY / ABSTRACT - STREAM DX Lower urinary tract symptoms (LUTS) is one of the most common medical problems among older men – affecting 33% of men by the time they reach 50 years of age and 75% by the time they reach the age of 80. LUTS is a progressive disease that has been shown to significantly increase the risk of depression and reduce quality of life. Early detection, intervention and active management is critical to successful treatment of LUTS. Uroflowmetry is an important and ubiquitous test in the diagnosis, monitoring, and post-treatment evaluation of men with LUTS. Uroflowmeters are devices that collect a complete urine void and then generate graphs that characterize the volume and flow rate pattern of the void. From these graphs, physicians should be able to identify the peak urinary flow (Qmax) which is the best single measure to predict whether a patient’s urine stream is obstructed. However, there are serious limitations and inherent pitfalls to uroflowmetry testing done in-clinic. First, having patients void in an artificial and unfamiliar clinic setting resulting in a different flow characteristic compared to having them void at home. Second, in-clinic testing results in a high number of uninterpretable voids when the patient can’t void enough in the unfamiliar setting. Uninterpretable voids are not billable by the care provider and the time spent attempting to collect this data in the clinic is wasted, creating frustration for the patient and the clinicians. Third, disabled, rural and elderly patients often have difficulty in getting to the doctor’s office exacerbating the testing process further. Stream Dx, Inc. has developed a low-cost, clinically accurate electronic flowmeter for at-home use, SDX01. The device is patented, registered with the FDA and has been introduced to the marketplace. It is an early stage uroflowmeter which accurately generates the same volume and flow data that is collected by in-clinic uroflowmeters but can store multiple days’ worth of patient void data in memory. SDX01 collects the data for each void, which is then either uploaded by the patient or Stream Dx to the company’s web-based portal for clinician viewing. The clinician can them immediately address concerns directly with the patient. In this Phase IIb proposal, Stream Dx will significantly improve the product and reduce costs while maintaining clinical accuracy. We expect to improve the device and data by adding fluid consumption as well as collecting additional urine flow data. We will migrate data transfer to a wireless cellular enabled IoT communications hub via Bluetooth 5.0. for real time access to patient data. These are non-irritative improvements and key to assuring patient usability and outcomes, maximize clinician time and patient interactions, ultimately producing the gold standard product. Today, none of the existing devices or apps in this area have a focus on monitoring the relationship of fluid intake to urine outflow, provide patient notifications to improve patient compliance, provide physician alerts or can collect urinalysis or other physiological data in future applications. When this Phase IIb is complete, Stream Dx’s SDX01 will be the gold standard in the monitoring and treatments of LUTS and be integrated into the marketplace across the U.S.PROJECT NARRATIVE / PUBLIC HEALTH RELEVANCE Lower urinary tract symptoms (LUTS) is one of the most common medical problems among older men – affecting 33% of men by the time they reach 50 years of age and 75% by the time they reach the age of 80. Uroflowmetry plays an important role in the diagnosis, monitoring, and post-treatment evaluation of men with LUTS as peak urinary flow rate is the single best measure to evaluate the probability of a patient being urodynamically obstructed. In order to bridge the gap between inexpensive devices that obtain limited flow data and expensive devices with the capabilities of clinic uroflowmeters, Stream Dx Inc. has developed a low-cost, clinically accurate electronic flowmeter for at-home use. Voiding diaries, which include frequency, volume voided, and fluid consumption during several 24-hour periods, are necessary in identifying and treating LUTS.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2017–2019). Reported award amounts total $4,464,557. Reported amounts are not federal obligations.

Phases: Phase II – Direct to Phase II, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.